Notable APAC license and supply agreement for QUVIVIQ\u00ae, with Synmosa to lead regulatory approvals, market access and sales across the specified APAC territories; Nxera Pharma Group will supply product and provide regulatory support. Nxera is entitled to upfront payments, approval-based milestones, royalties and product supply revenue. Impact is included in the consolidated earnings guidance disclosed on February 13, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nxera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4565-20261014-01.pdf","jir_short_summary":"Notable APAC license and supply agreement for QUVIVIQ\u00ae, with Synmosa to lead regulatory approvals, market access and sales across the specified APAC territories; Nxera Pharma Group will supply product and provide regulatory support. Nxera is entitled to upfront payments, approval-based milestones, royalties and product supply revenue. Impact is included in the consolidated earnings guidance disclosed on February 13, 2026.","jir_summary":"### Partnership Overview\nNxera Pharma Co., Ltd., through a subsidiary, has entered into an exclusive license, supply and commercialization agreement with Synmosa Biopharma Corporation for the insomnia treatment QUVIVIQ\u00ae (daridorexant) covering Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand. Synmosa will lead regulatory approvals, market access, distribution and sales in each country, while the Nxera Pharma Group will be responsible for formulation supply and regulatory support. As consideration under the agreement, Nxera is entitled to receive an upfront payment, approval-related milestone payments, royalties based on sales, and product supply revenue.\n\n### Impact on Earnings and Strategy\nThis transaction is expected to contribute to revenue growth and enhance corporate value over the medium to long term, and is explicitly incorporated into the consolidated earnings guidance disclosed on February 13, 2026. It strengthens the foundation for regulatory approvals and commercialization in Japan and across the APAC region as part of the company\u2019s strategy to expand its specialty pharmaceuticals business in the Asia-Pacific market.","jir_financial_highlights":"Upfront payment: Unknown (Unknown)\nRoyalties: Unknown (Unknown)\nProduct supply revenue: Unknown (Unknown)","jir_category":"","jir_hashtags":"#NxeraPharma, #PharmaceuticalPartnership, #AsiaPacificRegionExpansion","jir_key_figures":"Upfront payment: Unknown\nApproval-based milestones: Unknown\nRoyalties: Unknown","jir_meta_title":"Nxera Pharma: Exclusive APAC License Agreement with Synmosa for Insomnia Treatment QUVIVIQ\u00ae | October 2026","jir_meta_description":"Nxera Pharma has signed an exclusive license, supply and commercialization agreement with Synmosa for QUVIVIQ\u00ae in the Asia-Pacific region. Synmosa will lead approvals and market access; Nxera will receive upfront payments, milestones, royalties and supply revenue. Impact is reflected in the FY2026 earnings guidance.","jir_og_title":"Nxera Pharma Announces Exclusive APAC License Agreement for Insomnia Treatment with Synmosa","jir_og_description":"Nxera Pharma has announced an exclusive license agreement with Synmosa for QUVIVIQ\u00ae in APAC. Synmosa will handle local approvals and commercialization; Nxera will receive upfront, milestone, royalty and supply revenues.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-130763","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n